Romosozumab, a humanised monoclonal anti-sclerostin antibody, has been approved in osteoporosis, shows marked improvement in bone formation and bone mineral density, whilst decreasing bone resorption markers, and could be a potential agent for MBD [73]. The gene discussed is SOST; the disease is Marchiafava-Bignami disease.